Neurosterix

Financial Services · Biotechnology

Facts

as of Nov 17, 2026

Harnessing the power of allosteric modulators to design targeted, next-generation therapies for complex neuropsychiatric disorders.

Founded
2024
Employees
51-200estimated range
Website
neurosterix.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Milestones

2024
Founded
Each milestone is dated by its source: registers, filings, the press

Newsroom

top 7%Web presenceof 133.2M domains by links, Common Crawl
Apr 252026
News · pharmabiz.com
Addex spin-out company Neurosterix on track to complete phase 1 study of NTX-253 for schizophrenia in Q2 2026
Jan 72026
News · PRNewswire
PRN_FinancialWrapper
Apr 8, 20242024
News · healio.com
A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underse…
Apr 3, 20242024
Press release
The post Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders appeared first on Neurosterix.
Apr 3, 20242024
News · pharmaphorum
New biotech Neurosterix has been formed to develop allosteric modulators originated at Addex, including a candidate for schizophrenia.
Apr 2, 20242024
News · Nasdaq
(RTTNews) - Addex Therapeutics (ADXN) and funds affiliated with Perceptive Advisors announced the launch of Neurosterix, a company focused on developing allosteric modulators for…
Sources: the outlets named on each headline, each story once